stockrowDENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
- Revenue
- −7.52%
- EPS
- +99.5%
- Free cash flow
- −18.0%
- Total debt
- −1.59%
Quarter to September 2026, against a year earlier
Follow XRAY
Alert me
DENTSPLY SIRONA Inc. (XRAY) Return on equity
DENTSPLY SIRONA Inc.'s return on equity over the twelve months to 30 September 2026 was −8.55%, up 27.9 percentage points from fiscal 2025 (−36.4%). Over the past ten years it has ranged from −36.4% (fiscal 2025) to 10.8% (fiscal 2015) — the current reading is the lowest in ten years. That is below the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −36.4% | (1.68) |
| FY2024 | −34.8% | (31.03) |
| FY2023 | −3.72% | 17.85 |
| FY2022 | −21.6% | (29.85) |
| FY2021 | 8.28% | 9.74 |
| FY2020 | −1.46% | (6.47) |
| FY2019 | 5.01% | 22.20 |
| FY2018 | −17.2% | 3.82 |
| FY2017 | −21.0% | (29.23) |
| FY2016 | 8.22% | (2.56) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LMAT LeMaitre Vascular, Inc. compare | 15.6% |
| STVN Stevanato Group S.p.A. compare | 9.22% |
| ATRC AtriCure, Inc. compare | 2.95% |
| WRBY Warby Parker Inc. compare | 1.93% |
| STAA STAAR Surgical Company compare | 0.15% |
| AZTA Azenta, Inc. compare | −7.72% |
| XRAY DENTSPLY SIRONA Inc. | −8.55% |
| PLSE Pulse Biosciences, Inc compare | −60.7% |
| KMTS Kestra Medical Technologies, Ltd. compare | −73.7% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on XRAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement